DE69729201T2 - Sulfonfluoride zur behandlung von der alzheimerischen krankheit - Google Patents

Sulfonfluoride zur behandlung von der alzheimerischen krankheit Download PDF

Info

Publication number
DE69729201T2
DE69729201T2 DE69729201T DE69729201T DE69729201T2 DE 69729201 T2 DE69729201 T2 DE 69729201T2 DE 69729201 T DE69729201 T DE 69729201T DE 69729201 T DE69729201 T DE 69729201T DE 69729201 T2 DE69729201 T2 DE 69729201T2
Authority
DE
Germany
Prior art keywords
treatment
fluoride
individual
disease
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69729201T
Other languages
English (en)
Other versions
DE69729201D1 (de
Inventor
Eugene Moss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas at Austin
Original Assignee
The University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas at Austin filed Critical The University of Texas at Austin
Application granted granted Critical
Publication of DE69729201D1 publication Critical patent/DE69729201D1/de
Publication of DE69729201T2 publication Critical patent/DE69729201T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69729201T 1996-08-28 1997-08-26 Sulfonfluoride zur behandlung von der alzheimerischen krankheit Expired - Lifetime DE69729201T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08705858 US5798392C1 (en) 1996-08-28 1996-08-28 Sulfonyl fluorides for the treatment of alzheimer's disease
PCT/US1997/015024 WO1998008497A1 (en) 1996-08-28 1997-08-26 Sulfonyl fluorides for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
DE69729201D1 DE69729201D1 (de) 2004-06-24
DE69729201T2 true DE69729201T2 (de) 2005-04-21

Family

ID=24835244

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69729201T Expired - Lifetime DE69729201T2 (de) 1996-08-28 1997-08-26 Sulfonfluoride zur behandlung von der alzheimerischen krankheit

Country Status (8)

Country Link
US (1) US5798392C1 (de)
EP (1) EP0921790B1 (de)
JP (1) JP2000517317A (de)
AT (1) ATE267010T1 (de)
AU (1) AU731755B2 (de)
CA (1) CA2264582C (de)
DE (1) DE69729201T2 (de)
WO (1) WO1998008497A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045005A1 (en) * 2000-10-17 2003-03-06 Michael Seul Light-controlled electrokinetic assembly of particles near surfaces
EP1385520A4 (de) * 2001-02-08 2007-03-21 Nps Pharma Inc Methoden und verbindungen zur behandlung von neurologischen und neuropsychiatrischen erkrankungen und zur identifizierung von verbindungen zur behandlung derselben
US8618167B2 (en) * 2001-11-06 2013-12-31 Board Of Regents, The University Of Texas System Methods of attenuating cognitive deficits with sulfonyl fluorides
US20100256243A1 (en) * 2009-04-03 2010-10-07 Federica Pericle Dosing Regimen for the Treatment of Alzheimer's Disease With Sulfonyl Fluorides
US8349376B1 (en) * 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
EP3628315A1 (de) 2018-09-28 2020-04-01 Université de Caen Normandie Kombination aus acetylcholinesterase-inhibitor und 5-ht4-rezeptoragonist als neuroprotektives mittel zur behandlung von neurodegenerativen krankheiten
KR20230165280A (ko) * 2021-04-01 2023-12-05 알.피.쉐러 테크놀러지즈 엘엘씨 제약 제제에서 음이온 킬레이트화제로서의 인지질

Also Published As

Publication number Publication date
ATE267010T1 (de) 2004-06-15
CA2264582C (en) 2009-01-06
EP0921790A4 (de) 2000-11-02
WO1998008497A1 (en) 1998-03-05
EP0921790A1 (de) 1999-06-16
AU4091597A (en) 1998-03-19
US5798392A (en) 1998-08-25
AU731755B2 (en) 2001-04-05
DE69729201D1 (de) 2004-06-24
JP2000517317A (ja) 2000-12-26
CA2264582A1 (en) 1998-03-05
EP0921790B1 (de) 2004-05-19
US5798392C1 (en) 2002-06-04

Similar Documents

Publication Publication Date Title
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
DE69815122D1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
ATE113846T1 (de) Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
NO179250C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktiv (+)--(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etylÅ-4-piperidinmetanol
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
ATE190496T1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
EP1007556A4 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69729201D1 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
PT754054E (pt) Proteina anti-restenose
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE69728536D1 (de) Zubereitungen enhaltend eine nitroneverbindung für die verwendung bei der behandlung von uveitis
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
DE69739482D1 (de) Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
DE69524388D1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
ATA77095A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen, enthaltend eine aktive gerinnungsfördernde stubstanz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition